William Blair Investment Management LLC cut its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 15.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,949,723 shares of the company's stock after selling 527,572 shares during the quarter. William Blair Investment Management LLC owned approximately 4.95% of Twist Bioscience worth $137,074,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of the stock. ARK Investment Management LLC lifted its stake in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period. State Street Corp increased its holdings in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after buying an additional 526,028 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after acquiring an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience in the 3rd quarter worth about $43,992,000. Finally, Wellington Management Group LLP raised its stake in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after buying an additional 521,272 shares during the period.
Insider Buying and Selling
In related news, Director Robert Chess sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total value of $250,000.00. Following the sale, the director now directly owns 16,641 shares of the company's stock, valued at approximately $832,050. This trade represents a 23.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares of the company's stock, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,552 shares of company stock valued at $1,500,289. 3.01% of the stock is owned by insiders.
Twist Bioscience Stock Performance
Shares of TWST stock traded up $0.84 during midday trading on Friday, hitting $42.89. The company had a trading volume of 1,319,967 shares, compared to its average volume of 923,444. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company's 50 day simple moving average is $45.41 and its 200 day simple moving average is $45.21.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.75) earnings per share. Research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.
Analyst Ratings Changes
TWST has been the topic of several research reports. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Barclays set a $58.00 price target on Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. increased their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $54.40.
Get Our Latest Research Report on TWST
Twist Bioscience Company Profile
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
